Finnish diabetes study tests popular Pill's Real-World impact
NCT ID NCT05443191
Summary
This study observed 50 adults with type 2 diabetes in Finland who were prescribed the oral medication Rybelsus® (semaglutide) by their doctor. Researchers tracked their blood sugar levels and weight over 8-10 months to see how the medication works in everyday life, outside of a controlled clinical trial. Participants filled out a simple questionnaire about their medication use during regular doctor visits.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aava Lääkärikeskus Kamppi
Helsinki, 00100, Finland
-
Master Centre for Finland
Helsinki, Finland, 00100, Finland
-
Master centre for France_Paris La défense cedex
Paris, La Défense, cedex, France
Conditions
Explore the condition pages connected to this study.